卡铂联合紫杉醇对老年晚期卵巢癌患者的临床疗效及血清HE4、CA125水平的影响

Clinical efficacy of carboplatin combined with paclitaxel chemotherapy on elderly advanced oophoroma patients

目的探讨卡铂联合紫杉醇对老年晚期卵巢癌患者的临床疗效及血清人附睾分泌蛋白4(HE4)、糖类抗原125(CA125)水平的影响。方法选择2013年2月到2015年2月收治的64例老年晚期卵巢癌患者,随机分为试验组和对照组,各32例。对照组患者给予顺铂联合紫杉醇化疗,试验组患者给予卡铂联合紫杉醇化疗,均治疗2个疗程。评价并比较两组患者临床疗效与治疗期间不良反应发生情况,观察两组患者治疗前后血清HE4和CA125水平及肿瘤转移率。结果试验组患者的有效率和疾病控制率分别为78.13%和96.88%,明显高于对照组(53.13%和75.00%),差异具有统计学意义(P<0.05)。治疗后,两组患者血清HE4、CA125水平均显著降低(P<0.05),其中试验组患者血清HE4、CA125水平明显低于对照组,差异具有统计学意义(P<0.05)。试验组患者的不良反应发生率为21.88%,明显低于对照组患者的56.25%,差异具有统计学意义(P<0.01)。治疗后,试验组患者的肿瘤转移率为15.63%,明显低于对照组的40.63%,差异具有统计学意义(P<0.05)。结论卡铂联合紫杉醇治疗老年晚期卵巢癌的临床疗效显著,能明显降低患者肿瘤转移率及血清HE4和CA125水平,不良反应发生率低,值得临床上推广应用。

Objective To evaluate the clinical efficacy of carboplatin combined with paclitaxel as chemotherapy, and its effect on serum HE4 and CA125 for elderly patients with advanced oophoroma. Methods A total of 64 elderly patients with advanced oophoroma from February 2013 to February 2015 were enrolled in this study. The subjects were divided into control group(n=32) and experiment group(n=32) randomly. The control group was treated with cisplatin combined with paclitaxel for 42 days, and the experiment group was treated with carboplatin combined with paclitaxel for 42 days. The clinical efficacy and adverse reactions of both two groups were compared. The serum HE4, CA125 levels of two groups before and after treatment and tumor metastasis rate were compared. Results The response rate and disease control rate in experiment group were 78.13% and 96.88%, which were significantly higher than those in control group(53.13% and 75.00%, P<0.05). The serum HE4, CA125 levels of both two groups were significantly decreased after treatment(P<0.05),which of experiment group were significantly lower than those of control group(P<0.05). The incidence of adverse reactions in experiment group was 21.88%, which was significantly less than that in control group(56.25%, P<0.01). The tumor metastasis rate in experiment group was 15.63%, which was significantly lower than that in control group(40.63%, P<0.05). Conclusion Carboplatin combined with paclitaxel as chemotherapy for elderly patients with advanced oophoroma can significantly reduce the serum HE4, CA125 levels. It has good clinical efficacy and lower incidence of adverse reactions.